Gut Microbiota‐Related Effects of Tanhuo Decoction in Acute Ischemic Stroke
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Abstract
Acute ischemic stroke (AIS) is a major cause of acquired adult disability and death. Our previous studies proved the efficacy and effectiveness of Tanhuo decoction (THD) on AIS. However, the therapeutic mechanism remains unclear. We recruited 49 AIS patients and 30 healthy people to explore the effects of THD+basic treatment on the poststroke gut microbiota of AIS patients using 16S rRNA sequencing, in which 23 patients received basic treatment (control group) and 26 patients received THD+basic treatment (THD group). By comparing the data before and after treatments, we found the THD group acquired better outcome than the control group on both clinical outcome indices and the characteristics of gut microbiota. In addition to the mediation on short‐chain fatty acid‐ (SCFA‐) producing bacteria in two groups, treatment in the THD group significantly decreased the lipopolysaccharide‐ (LPS‐) producing bacteria to reduce LPS biosynthesis. Besides, the complexity of the cooccurrence of gut microbiota and the competition among LPS‐producing bacteria and opportunistic pathogenetic bacteria were enhanced in the THD group. Treatment in the THD group also exhibited the potential in decreasing genes on the biosynthesis of trimethylamine (TMA), the precursor of Trimethylamine N‐oxide (TMAO), and increasing genes on the degradation of TMA, especially increasing trimethylamine‐corrinoid protein Co‐methyltransferase (mttB) which catabolizes TMA to methane. These results hinted that THD+basic treatment might exert its efficacy by mediating the gut microbiota and microbial metabolites, including LPS and TMAO that aggravate the sterile inflammation and platelet aggregation. Moreover, the well‐fitting regression model results in predicting the clinical outcome with the alteration of gut microbiota proved gut microbiota as a potential indicator of AIS and provided evidence of the communication between the gut and brain of AIS patients.Keywords
Funding Information
- National Natural Science Foundation of China (31671366, 32070667)
This publication has 51 references indexed in Scilit:
- The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43Nature Communications, 2013
- phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census DataPLOS ONE, 2013
- A travel guide to Cytoscape pluginsNature Methods, 2012
- Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed RatsPLOS ONE, 2012
- Metagenomic biomarker discovery and explanationGenome Biology, 2011
- Platelets as initiators and mediators of inflammation at the vessel wallThrombosis Research, 2011
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- Sterile inflammation: sensing and reacting to damageNature Reviews Immunology, 2010
- Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis IndexAnnals of the Rheumatic Diseases, 2009
- Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARBApplied and Environmental Microbiology, 2006